Peer Insights

Get clinical insight from allergists and ear, nose, and throat specialists (ENT) about their experiences with XHANCE. Dr. Ow, Dr. Murphy, Dr. Reh, Dr. Bedrosian, Dr. Siri, and Dr. Hill are paid consultants for Optinose.

Allergists discuss diagnosing nasal polyps

Allergists discuss diagnosing nasal polyps

Allergists describe their role in treating nasal polyps

Allergists describe their role in treating nasal polyps

Endoscopy Video Before and After

Allergists talk about their experience with XHANCE

An ENT discusses goals of reducing nasal polyp grade and improving symptoms

An ENT discusses goals of reducing nasal polyp grade and improving symptoms

In clinical trials, XHANCE significantly improved nasal congestion at Week 4 and significantly reduced bilateral polyp grade at Week 16 (coprimary endpoints)¹:

Average reduction in congestion using a 0-3 point scale: 0.62 XHANCE 372 mcg BID vs 0.24 EDS-placebo (P<0.001)
Average reduction of polyp grade in a clinical trial using a 0-3 point scale: 1.41 XHANCE 372 mcg BID vs 0.61 EDS-placebo (P<0.001)

Review These Data More Closely

The clinical trials for XHANCE evaluated over 1500 patients.²

View endoscopy videos taken before and after treatment with XHANCE.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local Nasal Effects: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Close monitoring for glaucoma and cataracts is warranted.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

ADVERSE REACTIONS:
The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

INDICATION AND USAGE: XHANCE is a corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

Please see full Prescribing Information, including Instructions for Use.

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2021.
Data on file. OptiNose US, Inc.